myelogenous


Also found in: Dictionary, Encyclopedia.

myelogenic

 [mi″ĕ-lo-jen´ik]
produced in the bone marrow.

my·e·lo·ge·net·ic

, myelogenic (mī'ĕ-lō-jĕ-net'ik, -jen'ik),
1. Relating to myelogenesis.
2. Produced by or originating in the bone marrow. Synonym(s): myelogenous

myelogenous

/my·elog·e·nous/ (mi″ĕ-loj´ĕ-nus) produced in bone marrow.

myelogenous

(mī′ə-lŏj′ə-nəs) also

myelogenic

(-lə-jĕn′ĭk)
adj.
Originating in or produced by the bone marrow.

myelogenous

[mī′əloj′ənəs]
pertaining to the cells produced in bone marrow or the tissue from which such cells originate. Also myelogenetic, myelogenic.

myelogenous

adjective Produced by or originating in the bone marrow. Cf Myeloid.

my·e·lo·ge·net·ic

, myelogenic (mī'ĕ-lō-jĕ-net'ik, -jen'ik)
1. Relating to myelogenesis.
2. Produced by or originating in the bone marrow.
Synonym(s): myelogenous.

myelogenic, myelogenous

produced in the bone marrow.

myelogenic leukemia
see myelocytic leukemia.

Patient discussion about myelogenous

Q. Are there any specific treatments for acute myeloid leukemia caused by myelofibrosis? My husband was diagnosed with these conditions. His oncologist believes his AML was caused by his myelofibrosis. (scarring of the bone marrow) This was shown on his bone marrow biopsy. Myelofibrosis is a myeloproliferative disorder. Meaning certain blood components, such as WBCs, RBCs, platelets increase significantly in the marrow.

A. Thanks for taking the time to reply to me. I'll see about inquiring his oncologists.
Lynda

More discussions about myelogenous
References in periodicals archive ?
Despite imatinib's success against chronic myelogenous leukemia, recent studies have found that the drug loses its effectiveness in about one-fifth of patients (SN: 6/17/06, p.
Cancer metabolism company Agios Pharmaceuticals (NasdaqGS:AGIO) reported on Monday the receipt of the US Food and Drug Administration's (FDA) Fast Track designation for AG-120 for the treatment of patients with acute myelogenous leukemia (AML) who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.
AbbVie, a global biopharmaceutical company, has revealed the results from a Phase two study of investigational compound, venetoclax (ABT-199/GDC-0199), in patients with acute myelogenous leukaemia during an oral presentation at the American Society of Hematology's 56th Annual Meeting, it was reported yesterday.
The early stage of chronic myelogenous leukemia (CML), a form of the disease accounting for 15 percent of adult cases, is fairly mild, says Vigneri.
The product is used to treat patients with acute myelogenous leukemia that harbour an isocitrate dehydrogenase-2 (IDH2) mutation.
In patients with low-grade chronic myelogenous leukemia (CML), it seemed to kill tumor cells like a heat-seeking missile destroys a target (SN: 12/11/99, p.